Also, who really cares! This new moleclue is a big maybe that they might actually have a drug to market in 7-15 years after doing the preclinicals, clinicals and FDA submissions after spending who knows how much to get there. Just what they need, more research to do, when they don't have the funds to finish what they currently have in hand. This is a company that needs a short term fix to get viable again, or they won't be around long enough to have a chance to pursue R&D in these kinds of time frames. If they don't, they'll probably get bought up by somebody who wants the lab equipment and space on a short lead time, and who could pay for the deal with the AIMM cash assets. I'd love to see oral tolerance work, but AIMM sure hasn't seemed to be able to prove it to date, and until they do, their drug portfolio isn't worth squat! They only trade at 60% of their book value. They only trade at 72% of their cash value. What this says is that the market values their drug portfolio negatively. ie.) they figure that AIMM will continue to squander money on what is probably worthless, and thus is worth significantly less than if you just sold everything and split the cash up among the shareholders, something which will probably never happen as the people in the company are true believers (or they wouldn't be in this business in the first place), they like taking home a paycheck, and their egos wouldn't permit it. These people are probably still convinced they have something, but the markets sure don't believe them anymore! To expect that this kind of news on a new molecule that is a decade out from the market with slim odds of ever making it to market should somehow drive the stock price is naive at best. If anything, given the way the markets feel about AIMM, this kind of news could drop the price as it just gives AIMM something else to waste money on. Sorry, but the AIMM realities are really harsh. Also, interesting that the ORGAN has given up posting on this thread. I'm curious if the SEC has ever tried to find out who inside AIMM leaked the news that their clinicals had failed a month before the news was officially announced. This kind of crap even gives AIMM that much less credibility in the markets. AIMM could announce a hundred promising drug prospects and it wouldn't help the stock price. Your only hope is if this next clinical is so stunningly positive that it makes the other failures look like a fluke, and even then, the markets will suspect a Bre-X seeding of the AIMM data. And, the FDA will want more full blown positive clinicals to discount the failed ones. Good luck, but don't hold your breath on this one, you'll certainly sufficate while you're waiting.
Rocketman |
